Inclusion Criteria:

          -  Radiographic evidence of renal cell carcinoma (any histologic subtype) without
             evidence of distant metastatic disease

          -  Patients must have clinical stage T2b-4 and/or N1, M0 disease

          -  Written informed consent and any locally-required authorization (e.g., HIPAA))
             obtained from the subject prior to performing any protocol-related procedures,
             including screening evaluations

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate normal organ and marrow function as defined below:

               -  Hemoglobin ≥ 8.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (≥ 1500 per mm3)

               -  Platelet count ≥ 100 x 109/L (≥100,000 per mm3)

               -  Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). This will not
                  apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent
                  hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis
                  or hepatic pathology), who will be allowed only in consultation with the study
                  sponsor.

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal

               -  Glomerular filtration rate > 40ml/min/1.73m2 as estimated by the Cockcroft-Gault
                  formula or creatinine clearance >50ml/min as determined by 24-hour urine
                  collection:

               -  Estimated creatinine clearance (Clcr) in mL/min by the Cockcroft-Gault (C-G):
                  {[140 - age ( years)]× weight (kg)}/{72 × serum creatinine (mg / dL)} ×0.85 for
                  female patients

          -  Female subjects must either be of non-reproductive potential (ie, post-menopausal by
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.

          -  Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site). Previous enrollment in the present study.

          -  Participation in another clinical study with an investigational product during the
             last 30 days.

          -  Prior systemic anti-cancer therapy of any kind for RCC, including but not limited to
             any approved agent or any previous treatment with a PD1 or PD-L1 inhibitor including
             durvalumab. No previous treatment with immunotherapy for any malignancy including
             cytokine, anti-tumor vaccine, T-cell activator, co-stimulator or immune checkpoint
             inhibitor.

          -  Evidence of metastatic renal cell carcinoma on imaging and/or biopsy. Involvement of
             regional lymph nodes is permitted.

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from an
             electrocardiogram (ECG) using Fridericia's Correction (QTcF).

               -  a. At Screening, a single ECG will be obtained on which QTcF must be <470 ms. In
                  case of clinically significant ECG abnormalities, including a QTcF value >470 ms,
                  2 additional 12-lead ECGs should be obtained over a brief period (eg, 30 minutes)
                  to confirm the finding.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid.

          -  Active or prior documented autoimmune disease within the past 2 years.

          -  Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)

          -  History of primary immunodeficiency

          -  History of allogeneic organ transplant

          -  History of hypersensitivity to durvalumab or any excipient

          -  History of hypersensitivity to tremelimumab or any excipient

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension (defined as
             >160/90 mmHg despite medical therapy), unstable angina pectoris (requiring nitrates),
             cardiac arrhythmia (NOT including controlled atrial fibrillation), active peptic ulcer
             disease or gastritis, active bleeding diathesis including any subject known to have
             evidence of acute or chronic hepatitis B, hepatitis C (detectable RNA) or human
             immunodeficiency virus (HIV), or psychiatric illness/social situations that would
             limit compliance with study requirements or compromise the ability of the subject to
             give written informed consent

          -  Known history of previous clinical diagnosis of tuberculosis

          -  History of leptomeningeal carcinomatosis

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab or tremelimumab

          -  Female subjects who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control

               -  Pregnant or breastfeeding women are excluded from this study.

          -  Subjects with uncontrolled seizures

          -  Subjects with known HIV, active hepatitis B, or active hepatitis C (detectable RNA).
             HIV-positive subjects on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with durvalumab and/or tremelimumab. In
             addition, these subjects are at increased risk of lethal infections when treated with
             immunosuppressive therapy.

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results